|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chemokine and chemotactic signals in dendritic cell migration显示文摘Dendritic cells (DCs) are professional antigen-presenting cells responsible for the activation of specific T-cell responses and for thedevelopment of immune tolerance. Immature DCs reside in peripheral tissues and specialize in antigen capture, whereas matureDCs reside mostly in the secondary lymphoid organs where they act as antigen-presenting cells. The correct localization of DCs isstrictly regulated by a large variety of chemotactic and nonchemotactic signals that include bacterial products, DAMPs (dangerassociated molecular patterns), complement proteins, lipids, and chemokines. These signals function both individually and inconcert, generating a complex regulatory network. This network is regulated at multiple levels through different strategies, such assynergistic interactions, proteolytic processing, and the actions of atypical chemokine receptors. Understanding this complexscenario will help to clarify the role of DCs in different pathological conditions, such as autoimmune diseases and cancers and willuncover new molecular targets for therapeutic interventions. | Laura Tiberio Annalisa Del Prete Tiziana Schioppa Francesca Sozio Daniela Bosisio Silvano Sozzani | 2018 | Cellular & Molecular Immunology2018，15，4： | 14 |
| 2 | Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease(NAFLD)has become the most common liver disorder in Western countries and is increasingly being recognized in developing nations.Fatty liver disease encompasses a spectrum of hepatic pathology,ranging from simple steatosis to non-alcoholic steatohepatitis,cirrhosis,hepatocellular carcinoma and end-stage liver disease.Moreover,NAFLD is often associated with other metabolic conditions,such as diabetes mellitus type 2,dyslipidemia and visceral obesity.The most recent guidelines suggest the management and treatment of patients with NAFLD considering both the liver disease and the associated metabolic co-morbidities.Diet and physical exercise are considered the first line of treatment for patients with NAFLD,but their results on therapeutic efficacy are often contrasting.Behavior therapy is necessary most of the time to achieve a sufficient result.Pharmacological therapy includes a wide variety of classes of molecules with different therapeutic targets and,often,little evidence supporting the real efficacy.Despite the abundance of clinical trials,NAFLD therapy remains a challenge for the scientific community,and there are no licensed therapies for NAFLD.Urgently,new pharmacological approaches are needed.Here,we will focus on the challenges facing actual therapeutic strategies and the most recent investigated molecules. | Alessandro Federico Claudio Zulli Ilario de Sio Anna Del Prete Marcello Dallio Mario Masarone Carmela Loguercio | 2014 | World Journal of Gastroenterology2014，20，45： | 10 |
| 3 | Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens显示文摘 | Kimmie Ng Josep Tabernero Jimmy Hwang Emilio Bajetta Sunil Sharma Salvatore A. Del Prete Edward R. Arrowsmith David P. Ryan Michaela Sedova Jin Jin Kamel Malek Charles S. Fuchs | 2013 | Clinical Cancer Research2013，，14： | 4 |
| 4 | WJH 6^(th) Anniversary Special Issues(4): Cirrhosis Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis显示文摘Ascites and hyponatremia are the most common complications in patients with liver cirrhosis and develop as a consequence of a severe impairment of liver function and portal hypertension. Increasing evidences support the central role of renal function alterations in the pathogenesis of hydroelectrolytic imbalances in cirrhotic patients, thus implying a dense cross-talk between liver and kidney in the systemic and splanchnic vascular homeostasis in such subjects. Since Arginin Vasopressin(AVP) hyperincretion occurs at late stage of cirrhosis and plays an important role in the development of refractory ascites, dilutional hyponatremia and finally hepato-renal syndrome, selective antagonists of AVP receptors V2(vaptans) have been recently introduced in the therapeutic algorithm of advanced cirrhotic patients. Despite the promising results of earlier phasetwo studies, randomized controlled trials failed to find significant results in terms of efficacy of such drugs both in refractory ascites and hyponatremia. Moreover, concerns on their safety profile arise, due to the number of potentially severe side effects of vaptans in the clinical setting, such as hypernatremia, dehydration, renal impairment, and osmotic demyelination syndrome. More robust data from randomized controlled trials are needed in order to confirm the potential role of vaptans in the management of advanced cirrhotic patients. | Antonio Facciorusso Annabianca Amoruso Viviana Neve Matteo Antonino Valentina Del Prete Michele Barone | 2014 | World Journal of Hepatology2014，6，11： | 4 |
| 5 | Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases显示文摘AIM: To test the correlation between lymphocyte-tomonocyte ratio(LMR) and survival after radiofrequency ablation(RFA) for colorectal liver metastasis(CLMs). METHODS: From July 2003 to Feb 2012, 127 consecutive patients with 193 histologically-proven unresectable CLMs were treated with percutaneous RFA at the University of Foggia. All patients had undergone primary colorectal tumor resection before RFA and received systemic chemotherapy. LMR was calculated by dividing lymphocyte count by monocyte count assessed at baseline. Treatment-related toxicity was defined as any adverse events occurred within 4 wk after the procedure. Overall survival(OS) and time to recurrence(TTR) were estimated from the date of RFA by Kaplan-Meier with plots and median(95%CI). The inferential analysis for time to event data was conducted using the Cox univariate and multivariate regression model to estimate hazard ratios(HR) and 95%CI. Statistically significant variables from the univariate Cox analysis were considered for the multivariate models.RESULTS: Median age was 66 years(range 38-88) and patients were prevalently male(69.2%). Median LMR was 4.38%(0.79-88) whereas median number of nodules was 2(1-3) with a median maximum diameter of 27 mm(10-45). Median OS was 38 mo(34-53) and survival rate(SR) was 89.4%, 40.4% and 33.3% at 1, 4 and 5 years respectively in the whole cohort. Running log-rank test analysis found 3.96% as the most significant prognostic cut-off point for LMR and stratifying the study population by this LMR value median OS resulted 55 mo(37-69) in patients with LMR > 3.96% and 34(26-39) mo in patients with LMR ≤ 3.96%(HR = 0.53, 0.34-0.85, P = 0.007). Nodule size and LMR were the only significant predictors for OS in multivariate analysis. Median TTR was 29 mo(22-35) with a recurrence-free survival(RFS) rate of 72.6%, 32.1% and 21.8% at 1, 4 and 5 years, respectively in the whole study group. Nodule size and LMR were confirmed as significant prognostic factors for TTR in multivariate Cox regression. TTR, when stratified by LMR, was 35 mo(28-57) in the group > 3.96% and 25 mo(18-30) in the group ≤ 3.96%(P = 0.02).CONCLUSION: Our study provides support for the use of LMR as a novel predictor of outcome for CLM patients. | Antonio Facciorusso Valentina Del Prete Nicola Crucinio Gaetano Serviddio Gianluigi Vendemiale Nicola Muscatiello | 2016 | World Journal of Gastroenterology2016，22，16： | 4 |
| 6 | Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?显示文摘Cancer treatment has been revolutionized by the advent of new molecular targeted and immunotherapeutic agents. Identification of the role of tumor angiogenesis changed the understanding of many tumors. After the unsuccessful results with chemotherapy, sorafenib, by interfering with angiogenic pathways, has become pivotal in the treatment of hepatocellular carcinoma. Sorafenib is the only systemic treatment to show a modest but statistically significant survival benefit. All novel drugs and strategies for treatment of advanced hepatocellular carcinoma must be compared with the results obtained with sorafenib, but no new drug or drug combination has yet achieved better results. In our opinion, the efforts to impact the natural history of the disease will be directed not only to drug development but also to understanding the underlying liver disease(usually hepatitis B virus- or hepatitis C virus-related) and to interrupting the progression of cirrhosis. It will be important to define the role and amount of mutations in the complex pathogenesis of hepatocellular carcinoma and to better integrate locoregional and systemic therapies. It will be important also to optimize the therapeutic strategies with existing chemotherapeutic drugs and new targeted agents. | Liliana Montella Giovannella Palmieri Raffaele Addeo Salvatore Del Prete | 2016 | World Journal of Gastroenterology2016，22，27： | 3 |
| 7 | Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation显示文摘 | Antonio Facciorusso Valentina Del Prete Matteo Antonino Nicola Crucinio Viviana Neve Alfredo Di Leo Brian I. Carr Michele Barone | 2014 | Digestive and Liver Disease2014，，11： | 2 |
| 8 | Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients显示文摘 | Antonio Facciorusso Valentina Del Prete Nicola Crucinio Nicola Muscatiello Brian I Carr Alfredo Di Leo Michele Barone | 2015 | J Gastroenterol Hepatol2015，，11： | 2 |
| 9 | Polidocanol injection decreases the bleeding rate after colon polypectomy: a propensity score analysis显示文摘 | Antonio Facciorusso Marianna Di Maso Matteo Antonino Valentina Del Prete Carmine Panella Michele Barone Nicola Muscatiello | 2015 | Gastrointestinal Endoscopy2015，，2： | 2 |
| 10 | Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma显示文摘 | S. Fiorino S. Lorenzini M. Masetti G. Deleonardi A.G. Grondona T. Silvestri E. Chili P. Del Prete L. Bacchi-Reggiani A. Cuppini E. Jovine | 2012 | Medical Hypotheses2012，，5： | 2 |
| 11 | Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options显示文摘 | Luca Faloppi Mario Scartozzi Elena Maccaroni Marzia Di Pietro Paolo Rossana Berardi Michela Del Prete Stefano Cascinu | 2010 | Cancer Treatment Reviews2010，，3： | 2 |
| 12 | Combination studies between polycationic peptides and clinically used antibiotics against Gram-positive and Gram-negative bacteria 显示文摘 | Giacometti A Cirioni () Del Prete M S | 2000 | Peptides2000，21，： | 2 |
| 13 | Dendritic cell-mediated cross presentation of antigens derived from colon carcinoma cells exposed to a highly eytotoxie multidrug regimen with gemcitabine, oxaliplatin, 5 fluorouracil,and leucovorin, elicits a powerful human antigenspecific CTL response with antitumor activity in vitro显示文摘 | Correale P Cusi M G Del Vecchio M T Aquino A Prete S P Tsang K Y | 2005 | J Immunol2005，175，： | 1 |
| 14 | Hypot halamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid art hritis not t reated wit h glucocorticoids显示文摘 | Cutolo M Foppiani L Prete C | 1999 | Jrheumatol1999，26，2： | 1 |
| 15 | Helicobacter pylori infection and gastric MALTomas: an up-to- date and therapy highlight 显示文摘 | SANTACROCE L CAGIANO R DEL PRETE R | 2008 | Clin Ther2008，159，6： | 1 |
| 16 | Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production 显示文摘 | Del Prete G Carli M Almerigogna F | 1993 | J Immunol1993，150，2： | 1 |
| 17 | The possible role of ChemR23/Chemerin axisin the recruitment of dendritic cells in lupus nephritis显示文摘 | DE PALMA G CASTELLANO G DEL PRETE A | 2011 | Kidney Int2011，79，11： | 1 |
| 18 | Preferential expression of CD30 by human CD4 + T cells producing Th - 2 type cytokines显示文摘 | Del Prete GF De Carli M Almerigogna F | 1995 | FASEB J1995，9，1： | 1 |
| 19 | Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines显示文摘 | Del Prete G De Carli M Almerigogna F | 1995 | FASEB J1995，9，： | 1 |
| 20 | Unusual clinical presentation of infection due toFlavimonas oryzihabitans显示文摘 | A. Giacometti O. Cirioni M. Quarta A. M. Schimizzi M. S. Prete G. Scalise | 1998 | European Journal of Clinical Microbiology & Infectious Diseases1998，，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员